“I know where I am, and I know where I’m going and I know I’m going to get there. I’m going to be excited and enthusiastic every day that God gives me on this earth. I am going to dream my dreams.”

- JIM VALVANO
The V Foundation for Cancer Research is a charitable organization dedicated to saving lives by helping to find cures for cancer. The V Foundation strives to make a difference by generating extensive, passionate support for cancer research and by creating an urgent awareness among all Americans of the importance of ending the disease in all its forms. The dedicated work of our many partners, volunteers and supporters has led to many extraordinary, tangible victories in the war against cancer. Through advocacy, education, fundraising, and philanthropy, The V Foundation continues to seize every opportunity to change lives and ultimately defeat cancer.

The V Foundation has spent 21 years funding research that brings together the brightest minds working to end cancer. We are proud to present our annual report, providing a snapshot of last year’s accomplishments. During fiscal year 2013, we funded $14 million in new cancer research grants, and continue to fund previous multi-year grants. We are making important progress! This report is also a prelude to the future – a look at how to expedite this fight, to make it as effective as possible, to enlist each of you in this effort so that we can end cancer. Thank you for your help and support. No one can change the course of cancer alone. We dedicate this report to everyone working together toward this goal. Please help us continue until there is no longer a need.

Susan Braun
Chief Executive Officer
The V Foundation awards three types of grants. The V Scholar grant directly funds young investigators to help them establish their own independent laboratory research projects. The Translational grant facilitates the transition of projects from the laboratory to the patient’s beside quickly and efficiently. The Designated grants are inspired by particular areas of scientific interest and/or geographic reach. They are selected on the basis of scientific merit, as determined by our scientific advisors.

**V Scholars**

Bjoern Schwer, M.D., Ph.D.  
Boston Children's Hospital  
Boston, MA  
Martin D. Abeloff, M.D. V Scholar  
*Neural Genome Rearrangements and Alternative end Joining Processes in Initiation and Maintenance of Medulloblastoma*

Maximilian Diehn, M.D., Ph.D.  
Stanford Cancer Institute  
Stanford, CA  
*Investigating the KEAP1-NRF2 Pathway in Lung Stem Cells and Lung Cancer*  
Albert Wyrick V Scholar Award  
Funded by The Michael and Carole Marks Family

Rafael Bejar, M.D., Ph.D.  
UCSD Moores Cancer Center  
La Jolla, CA  
*Pathogenic Mechanisms of Splicing Factor Mutations in Myelodysplastic Syndromes*

Timothy F. Burns, M.D., Ph.D.  
University of Pittsburgh Cancer Institute  
Pittsburgh, PA  
*Targeting KRAS Mutant Lung Adenocarcinoma through Inhibition of TWIST 1*  
Supported by UNICO National in Memory of Sue Speciale

Luis Carvajal-Carmona, Ph.D.  
University of California, Davis  
Sacramento, CA  
*Identification of Novel Breast Cancer Genes in a Hispanic Isolate*

Robert Doebele, M.D., Ph.D.  
University of Colorado School of Medicine  
Department of Medicine, Division of Medical Oncology  
Aurora, CO  
*NTRK1 Gene Fusions as a Novel Oncogene Class and Therapeutic Target in Lung Cancer*  
Funded in Memory of Calvin Bradham with support from Crown Imports

Michael J. Emanuele, Ph.D.  
Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill  
Chapel Hill, NC  
*Identification of Ubiquitin Signaling Networks as Novel Avenues for Therapeutic Intervention*

Summer Gibbs, Ph.D.  
Oregon Health & Science University  
Portland, OR  
*Screening of Small Molecule Fluorophores to Probe Pancreatic Cancer Margins in the Operating Room*
Peter Hammerman, M.D., Ph.D.
Dana-Farber Cancer Institute
Boston, MA
Targeting Fibroblast Growth Factor Receptor Fusions in Lung and Head and Neck Cancer

Mei Kong, Ph.D.
Beckman Research Institute of the City of Hope Duarte, CA
Targeting Glutamine Metabolism and the B55a-p53 Survival Pathway for Lymphoma Treatment

Christopher A. Maher, Ph.D.
Siteman Cancer Center
Washington University
St. Louis, MO
Understanding the Role of Polycomb Associated LncRNAs in Prostate Cancer
2013 Vintner Grant – Funded by The Wine Celebration
In Honor of Fred and Mary Constant, Jeff and Valerie Gargiulo, Dick and Ann Grace, Fred and Sally Schweiger, and Lowell and Janet Herrera

Michael Kharas, Ph.D.
Memorial Sloan-Kettering Cancer Center
New York, NY
Understanding the MSI2 RNA Binding Protein Network in Leukemia

George-Lucian Moldovan, Ph.D.
Penn State Hershey Cancer Institute
Hershey, PA
Dysregulation of the PARI Genomic Stability Pathway in Leukemia

Zeshaan Rasheed, M.D., Ph.D.
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Regulatory Effects of the Tumor Microenvironment on Stem Cell Plasticity in Pancreatic Ductal Adenocarcinoma

Jatin Roper, M.D.
Tufts Medical Center
Boston, MA
The Role of IWS1 and FGFR2 Isoform IIIC in Akt Isoform-dependent Colorectal Carcinogenesis

Ryan A. Wilcox, M.D., Ph.D.
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI
Role of the T-cell Transcription Factor GATA-3 in Cutaneous T-cell Lymphomas

Kris C. Wood, Ph.D.
Duke Cancer Institute
Durham, NC
Systematic Identification of Combination Therapies Targeting the Breast Cancer Microenvironment
2013 V Foundation Wine Celebration Volunteer Grant in Honor of John and Anne Sachs

Chunling Yi, Ph.D.
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC
Interrogating the Role of Hippo-Yap Growth Regulatory Pathway in Kidney Cancer
2013 TRANSLATIONAL GRANTS

Nika Danial, Ph.D.
Margaret Shipp, M.D.
Jarrod Marto, Ph.D.
Dana-Farber Cancer Institute
Boston, MA
Fueling DLBCL Proliferation and Survival: A Role for Fatty Acid Metabolism

Ralph Deberardinis, M.D., Ph.D.
Kemp Kernstein, M.D., Ph.D.
Children’s Medical Center Research Institute at University of Texas Southwestern
Dallas, TX
Funded in Memory of Christopher T. Carroll
Translational Studies in Lung Cancer Metabolism: Creating New Paradigms in Diagnosis and Therapy

Gianpietro Dotti, M.D.
Cliona Rooney, Ph.D.
Caridad Martinez, M.D.
Dan L. Duncan Cancer Center at Baylor College of Medicine
Houston, TX
Prevention and Treatment of Viral Infections and Leukemic Relapse after Allogeneic Stem Cell Transplantation

Benjamin L. Ebert, M.D., Ph.D.
Ann Mullally, M.D.
William Kaelin, Jr., M.D.
David Steensma, M.D.
Brigham and Women’s Hospital
Boston, MA
Identifying and Targeting Oncogenic Pathways in TET2 and IDH Mutant Myeloid Malignancies

Tanja A. Gruber, M.D., Ph.D.
James R. Downing, M.D.
St. Jude Children’s Research Hospital
Memphis, TN
Funded by the 2013 Dick Vitale Gala
In Honor of Dick and Lorraine Vitale
Identification of Active Compounds in Infantile Acute Lymphoblastic Leukemia

John V. Heymach, M.D., Ph.D.
Varsha Gandhi, Ph.D.
Christine Stellrecht, Ph.D.
Carlo Tonietti, M.D., Ph.D.
Timothy Heffernan, Ph.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
Attacking the Specific Vulnerability of LKB1-Mutant NSCLC to Energy Depletion Using an ATP Mimetic

Ite A Laird-Offringa, Ph.D.
Barbara Gitlitz, M.D.
Martin W. Kast, Ph.D.
Kimberly Siegmund, Ph.D.
Lina Wang, M.D.
Michael Wong, M.D., Ph.D.
USC Norris Comprehensive Cancer Center
Los Angeles, CA
Development of Immunotherapy for Small Cell Lung Cancer using Novel Modified Antigens

Daniela Matei, M.D.
Kenneth P. Nephew, Ph.D.
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, IN
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer

Toshi Taniiguchi, M.D., Ph.D.
Elizabeth M. Swisher, M.D.
Fred Hutchinson Cancer Center
Seattle, WA
Defining Genomic Scarring and Functional DNA Variants that Predict Response to PARP Inhibitors in a Clinical Trial for Recurrent Ovarian Cancer

Pengbo Zhou, Ph.D.
Leonard Salta, M.D.
Yao-Tseng Chen, M.D., Ph.D.
Weill Cornell Medical College
New York, NY
Ubiquitin Ligase as a Novel Diagnostic Marker and Therapeutic Target for Colorectal Cancer
Funded by The V Foundation Wine Celebration
In Honor of Steve Bornstein
## 2013 DESIGNATED GRANTS

**Lizi Wu, Ph.D.**  
Shands Cancer Center  
University of Florida  
Gainesville, FL  
*Regulation of Oncogenic NOTCH Signaling in Childhood Leukemia*  
Funded by 2012 Dick Vitale Gala  
In Memory of Caleb Gacobbe

**Daniel S. Wechsler, M.D., Ph.D.**  
Duke University Medical Center  
Durham, NC  
*Therapeutic Targeting of Calm-AF10 Nuclear Export in Pediatric Leukemia*  
Funded by The Apple Gold Group

**Stuart Goldberg, M.D.**  
Hackensack University Medical Center  
The John Theurer Cancer Center  
Hackensack, NJ  
*The Use of Dynamic Single Cell Network Profile to Predict Outcome in Newly Diagnosed Acute Myelogenous Leukemia (AML)*  
Funded by Marketing Research Consultants  
In Memory of Mary Ann Ingoglia

**Victoria Belancio, Ph.D.**  
Tulane University  
Tulane Cancer Center  
New Orleans, LA  
*Line-1 Contributing to Lung Cancer in Vivo*  
Funded by The Kay Yow Cancer Fund

**Shari Pilon-Thomas, Ph.D.**  
William E. Janssen, M.D.  
H. Lee Moffitt Cancer Center & Research Institute  
Tampa, FL  
*Adoptive Cell Therapy for Neuroblastoma*  
Funded by 2012 Dick Vitale Gala  
In memory of Dave Heard

**Queen of the Valley Medical Center**  
Napa, CA  
Funded by The V Foundation Wine Celebration  
*Clinical Laboratory and Pathology Services*  
*Herman Family Advanced Diagnostic and Surgical Services Pavilion*

**Amit K. Verma, M.D.**  
David J. Prezant, M.D.  
Mayris Prezant, M.D., Dr. P.H.  
Charles B. Hall, Ph.D.  
Albert Einstein College of Medicine of Yeshiva University  
Bronx, NY  
*Early Detection of Hematologic Malignancies in New York City Firefighters Exposed to World Trade Center Dust after the 9/11 Attacks*  
Funded by The V Foundation Wine Celebration and Jimmy V Celebrity Golf Classic

**St. Helena Hospital**  
Napa, CA  
Clinical Research Program at St. Helena Hospital Martin-O’Neil Cancer Center  
Funded by The V Foundation Wine Celebration

**Calvin Lee, M.D.**  
All Children’s Hospital  
St. Petersburg, FL  
*BMI1’s Role in the Regulation of Myogenic Differentiation in Rhabdomyosarcoma*  
Funded by 2013 Dick Vitale Gala

**John Cavanagh, Ph.D.**  
North Carolina State Jimmy V Cancer Therapeutics Program  
Raleigh, NC  
Funded by 2013 Jimmy V Celebrity Golf Classic  
In Honor of the JVCGC 20 Year Volunteers

**James M. Ford, M.D.**  
Stanford University School of Medicine  
Stanford, CA  
Funded by The Gastric Cancer Foundation  
*Gastric Cancer Genomic Research*

**Daniel S. Wechsler, M.D., Ph.D.**  
Catherine P. Lavau, DVM, Ph.D.  
Duke University Medical Center  
Durham, NC  
*A Novel Role for the CRM1 Nuclear Export Receptor in Leukemogenesis: Mechanisms and Targeting*  
Funded by The Apple Gold Group
The V Foundation Board of Directors is entrusted with and accountable for the strategic leadership and governance of the organization. Comprised of prominent business leaders, award-winning athletes and coaches, distinguished physicians and world-renowned entertainers, the Board provides governance and insight into sustaining and continually improving the Foundation’s efforts in the fight against cancer.

<table>
<thead>
<tr>
<th>Jim Allegro</th>
<th>Rosa M. Gatti</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emeritus Director</td>
<td>Retired Senior Vice President, Communications Counsel and Corporate Outreach</td>
</tr>
<tr>
<td>The V Foundation for Cancer Research</td>
<td>ESPN, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Julie Allegro</th>
<th>Mark King</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Partner</td>
<td>President</td>
</tr>
<tr>
<td>Allegro Venture Partners</td>
<td>Adidas Group North America</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Robert C. Bast, Jr., M.D.</th>
<th>Philip H. Knight</th>
<th>Michael W. Krzyzewski</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vice President for Translational Research</td>
<td>Chairman of the Board</td>
<td>Head Coach, Men’s Basketball</td>
</tr>
<tr>
<td>The University of Texas</td>
<td>Nike, Inc.</td>
<td>Duke University</td>
</tr>
<tr>
<td>MD Anderson Cancer Center</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>George Bodenheimer</th>
<th>Eric Lautenbach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Chairman</td>
<td>Director of College Basketball Sports Marketing</td>
</tr>
<tr>
<td>ESPN, Inc.</td>
<td>Nike, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Steven M. Bornstein</th>
<th>Carl C. Liebert III</th>
<th>Joe Loughrey</th>
</tr>
</thead>
<tbody>
<tr>
<td>Former President and Chief Executive Officer</td>
<td>President</td>
<td>Retired President and Vice Chairman</td>
</tr>
<tr>
<td>NFL Network</td>
<td>USAA Capital Corporation</td>
<td>Cummins, Inc.</td>
</tr>
<tr>
<td>Board Chair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The V Foundation for Cancer Research</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bill Cosby</th>
<th>Robert E. Lloyd</th>
<th>Michael C. Mac Donald</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chair Emeritus</td>
<td>Chairman and Chief Executive Officer</td>
</tr>
<tr>
<td></td>
<td>The V Foundation for Cancer Research</td>
<td>Medifast</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>George W. Dennis III</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Retired Senior Partner</td>
<td>Board Chair</td>
</tr>
<tr>
<td>Teague Campbell Dennis &amp; Gorham, LLP</td>
<td>The V Foundation for Cancer Research</td>
</tr>
</tbody>
</table>
Michael E. Marks  
Founding Partner  
Riverwood Capital, LLC

Geoffrey S. Mason  
Senior Production Specialist  
ESPN, Inc.

Joseph O. Moore, M.D.  
Professor of Medicine  
Duke Cancer Institute

Robert C. Nakasone  
Retired Chief Executive Officer  
Toys “R” Us, Inc.

Donna Orender  
Chief Executive Officer  
Orender Unlimited, LLC

Lawrence F. Probst III  
Chairman of the Board  
Electronic Arts

Harry E. Rhoads, Jr.  
Chief Executive Officer  
Washington Speakers Bureau

Robin Roberts  
Co-Anchor  
ABC’s Good Morning America

John P. Saunders  
Sports Commentator  
ESPN, Inc. and ABC Sports

Constance Skidmore  
Retired Board Member – Managing Partner  
PricewaterhouseCoopers LLP

John Skipper  
Co-Chair  
Disney Media Networks  
President  
ESPN, Inc.

Tony F. Smith, Ph.D.  
Managing Director  
Leadership Research Institute

Pamela Valvano Strasser  
Chairwoman  
The V Foundation for Cancer Research

Stuart Taylor  
Chief Executive Officer  
The Taylor Group

Nicholas P. Valvano  
President Emeritus  
The V Foundation for Cancer Research

Robert Valvano  
Sports Commentator

Lesley Visser  
Sports Commentator  
CBS and HBO

Dick Vitale  
Sports Commentator  
ESPN, Inc. and ABC Sports

R.C. “Bucky” Waters  
Retired Vice Chancellor  
Duke University Medical Center

Robert P. Wayman  
Retired Chief Financial Officer and  
Executive Vice President  
Hewlett-Packard Company

Dereck Whittenburg  
Director of Player Development  
North Carolina State University

David W. Williams  
Retired Senior Vice President  
Whirlpool Corporation

Norby Williamson  
Executive Vice President,  
Programming & Acquisitions  
ESPN, Inc.

Larry Woodard  
President and Chief Executive Officer  
Graham Stanley Advertising

Susan Braun  
Ex Officio  
Chief Executive Officer  
The V Foundation for Cancer Research
Scientific Advisory Committee

The Scientific Advisory Committee is composed of leading physicians and research scientists from prominent universities and cancer centers. The all-volunteer Committee reviews and recommends top-rated research projects from the brightest innovators exploring the mysteries of cancer. Their guidance safeguards the scientific merit of grant proposals and ultimately provides funding to the leading pioneers in the field of cancer research.

Martin D. Abeloff, M.D.
(In Memoriam)
Sidney Kimmel
Comprehensive Cancer Center

H. Shelton Earp III, M.D.
UNC Lineberger
Comprehensive Cancer Center

Robert C. Bast, Jr., M.D.
The University of Texas
MD Anderson Cancer Center

Paul F. Engstrom, M.D.
Fox Chase Cancer Center

William T. Beck, Ph.D.
University of Illinois at Chicago

Olivera J. Finn, Ph.D.
University of Pittsburgh
School of Medicine

Lisa Coussens, Ph. D.
Oregon Health & Science University

Richard I. Fisher, M.D.
Fox Chase Cancer Center

Nancy Davidson, M.D.
University of Pittsburgh
Cancer Institute

James M. Ford, M.D.
Stanford University
School of Medicine
Susan Hilsenbeck, Ph.D.
Baylor College of Medicine

Richard O’Reilly, M.D.
Memorial Sloan-Kettering Cancer Center

Theodore S. Lawrence, M.D., Ph.D.
University of Michigan Comprehensive Cancer Center

David Piwinica-Worms, M.D., Ph.D.
The University of Texas MD Anderson Cancer Center

A. Thomas Look, M.D.
Dana-Farber Cancer Institute

Helen Piwinica-Worms, Ph.D.
The University of Texas MD Anderson Cancer Center

John D. Minna, M.D.
University of Texas Southwestern Medical Center

Jerome Ritz, M.D.
Dana-Farber Cancer Institute

Joseph O. Moore, M.D.
Duke Cancer Institute

David E. Schuller, M.D.
The Ohio State University Comprehensive Cancer Center

William G. Nelson, M.D., Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Jonathan W. Simons, M.D.
Prostate Cancer Foundation

Brian Patrick O’Neill, M.D.
Mayo Clinic Cancer Center

Margaret A. Tempero, M.D.
UCSF Comprehensive Cancer Center
### Statement of Financial Position

September 30, 2013

**Assets**

**CURRENT ASSETS:**

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$11,730,389</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>213,495</td>
</tr>
<tr>
<td>Promises to give, net</td>
<td>2,136,430</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>151,737</td>
</tr>
</tbody>
</table>

**TOTAL CURRENT ASSETS**

14,232,051

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Property and Equipment, Net</td>
<td>48,515</td>
</tr>
</tbody>
</table>

**OTHER ASSETS:**

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments</td>
<td>22,446,454</td>
</tr>
<tr>
<td>Promises to give, net</td>
<td>3,413,097</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>50,000</td>
</tr>
</tbody>
</table>

**TOTAL OTHER ASSETS**

25,909,551

**TOTAL ASSETS**

$40,190,117
Liabilities & Net Assets

**CURRENT LIABILITIES:**

Accounts payable and accrued expenses $ 55,188
Accrued payroll and related liabilities 53,968
Deferred rent 40,350
Grants payable 12,223,413

**TOTAL CURRENT LIABILITIES** 12,372,919

**LONG-TERM LIABILITIES:**

Grants payable, net 9,840,300

**TOTAL LIABILITIES** 22,213,219

**NET ASSETS:**

Unrestricted:
Board designated 5,517,136
Undesignated (3,589,825) 1,927,311
Temporarily restricted 3,932,576
Permanently restricted 12,117,011

**TOTAL NET ASSETS** 17,976,898

**TOTAL LIABILITIES AND NET ASSETS** $40,190,117
Statement of Activities and Changes in Net Assets

For the year ended September 30, 2013

**SUPPORT AND REVENUE:**

<table>
<thead>
<tr>
<th>Description</th>
<th>UNRESTRICTED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and gifts</td>
<td>$ 10,608,057</td>
</tr>
<tr>
<td>Special events:</td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>1,592,397</td>
</tr>
<tr>
<td>Event income</td>
<td>204,611</td>
</tr>
<tr>
<td>Less: costs of direct benefits to donors</td>
<td>(674,660)</td>
</tr>
<tr>
<td>Net revenues from special events</td>
<td>1,122,348</td>
</tr>
<tr>
<td>License income</td>
<td>3,332</td>
</tr>
<tr>
<td>Investment income, net of fees</td>
<td>117,605</td>
</tr>
<tr>
<td>Unrealized gain on investments</td>
<td>213,597</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>130,773</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>1,122,348</td>
</tr>
</tbody>
</table>

**TOTAL SUPPORT AND REVENUE**

18,278,103

**EXPENSES:**

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>15,138,098</td>
</tr>
<tr>
<td>Supporting Services:</td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>719,490</td>
</tr>
<tr>
<td>Fundraising expenses</td>
<td>1,071,164</td>
</tr>
<tr>
<td>Total Supporting Services</td>
<td>1,790,654</td>
</tr>
</tbody>
</table>

**TOTAL EXPENSES**

16,928,752

**CHANGES IN NET ASSETS**

1,349,351

**TRANSFER OF NET ASSETS**

3,785,000

**NET ASSETS - BEGINNING OF NEW YEAR**

(3,207,040)

**NET ASSETS - END OF YEAR**

$1,927,311
<table>
<thead>
<tr>
<th>Temporary Restricted</th>
<th>Permanently Restricted</th>
<th>2013 Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ 5,085,610</td>
<td>$ 145,899</td>
<td>$ 15,839,566</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,592,397</td>
</tr>
<tr>
<td></td>
<td></td>
<td>204,611</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(674,660)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,122,348</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3,332</td>
</tr>
<tr>
<td></td>
<td>266,906</td>
<td>384,511</td>
</tr>
<tr>
<td></td>
<td>513,399</td>
<td>726,996</td>
</tr>
<tr>
<td></td>
<td>314,326</td>
<td>445,099</td>
</tr>
<tr>
<td></td>
<td>6,180,241</td>
<td>18,521,852</td>
</tr>
<tr>
<td></td>
<td>(6,082,391)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>97,850</td>
<td>18,521,852</td>
</tr>
<tr>
<td></td>
<td>145,899</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>15,138,098</td>
</tr>
<tr>
<td></td>
<td></td>
<td>719,490</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,071,164</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1,790,654</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16,928,752</td>
</tr>
<tr>
<td></td>
<td>97,850</td>
<td>1,593,100</td>
</tr>
<tr>
<td></td>
<td>145,899</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(3,785,000)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3,834,726</td>
<td>16,383,798</td>
</tr>
<tr>
<td></td>
<td>15,756,112</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$3,932,576</td>
<td>$17,976,898</td>
</tr>
<tr>
<td></td>
<td>$12,117,011</td>
<td></td>
</tr>
</tbody>
</table>
Grant Distribution by State

1994-2013
Grant Distributions by Cancer Site

1994-2013 (IN MILLIONS)

General Cancer/Other ($23.5) 181
Leukemia/Lymphoma ($22.1) 78
Breast ($10.9) 55
Pediatric ($14.1) 50
Lung ($11.6) 39
GI ($4.0) 28
Prostate ($4.6) 25
Melanoma ($6.3) 17
Pancreatic ($5.5) 15
Brain ($3.3) 11
Gyn./Cervical/Ovarian ($3.1) 10
Renal ($2.9) 8
Head and Neck ($1.4) 6
Myeloma ($0.5) 6
Colon ($1.2) 5
Ewings ($0.8) 5

539 TOTAL GRANTS

$115,436,054
Thank You

Thank You for Your Passion, Friendship and Commitment!

People from all walks of life support The V Foundation for Cancer Research.

Your donations are making an impact, advancing life-saving research and providing hope to cancer patients and their loved ones.

Thank you for caring and for all the good things you do to support our cause.

Together, we will win the fight against cancer.
HOPE
Begins in the dark.
The road is long.
The hills are steep.
Only your support drives us forward.